Duodenal-type follicular lymphoma more than 10 years after treatment intervention: A retrospective single-center analysis

doi:10.4251/wjgo.v14.i8.1552

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 14, Issue 8

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (4159)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Figures (1-3) series, Tables (1-2) series.

Item

Count

PDF

209

WORD

HTML

2286

Figures (1-3)

178

Tables (1-2)

155

Sum=2884

Publishing Process of This Article

The chart showing Browse series, Download series.

Item

Count

Browse

362

Download

913

Sum=1275

Aug 15, 2022 (publication date) through Jun 29, 2024

Times Cited of This Article

Times Cited (2)

Journal Information of This Article

Publication Name

World Journal of Gastrointestinal Oncology

ISSN

1948-5204

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Observational Study

World J Gastrointest Oncol. Aug 15, 2022; 14(8): 1552-1561
Published online Aug 15, 2022. doi: 10.4251/wjgo.v14.i8.1552

Table 2 Treatment and outcome of 5 patients

Case	Treatment motive	Initial treatment	Effect	Rituximab maintenance	Relapse lesion/re-Stage (from the end of treatment)	2^nd treatment	Outcome (from the 1^st onset)
1	Previously followed doctor’s judgment	RTX	1^st CR	(-)	Duodenum + cervical LN/Stage IV (1 yr and 3 mo)	R-THP-COP	2^ndCR (18 years)
2	In stage IV	R-CVP + R-F	1^st CR	(+)	Colon + mesenteric LN/Stage II1 (1 yr and 7 mo)	Watch	2^ndCR (12 yr)
3	In stage IV	R-CHOP	1^st CR	(+)	(-)	-	1^stCR (13 yr)
4	Patient’s request	Radiation + RTX	1^st CR	(-)	(-)	-	1^stCR (16 yr)
5	Patient’s request	CHOP/RTX/radiation	1^st CR	(-)	Lung + systemic LN/Stage IV (13 yr)	B-R/R-BAC/CHOEP/ONTZ	Death due to primary disease (21 yr)

RTX: Rituximab; R-CVP: Rituximab + cyclophosphamide, vincristine, and prednisone; R-F: Rituximab + oral fludarabine; R-CHOP: Rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone; R-THP-COP: Rituximab, cyclophosphamide, pirarubicin, vincristine, and prednisone; B-R: Rituximab + bendamustine; R-BAC: Rituximab, bendamustine, and cytarabine; CHOEP: Cyclophosphamide, doxorubicin, vincristine, etoposide, and prednisone; ONTZ: Obinutuzumab; LN: Lymph node; CR: Complete remission.

Citation: Saito M, Mori A, Tsukamoto S, Ishio T, Yokoyama E, Izumiyama K, Morioka M, Kondo T, Sugino H. Duodenal-type follicular lymphoma more than 10 years after treatment intervention: A retrospective single-center analysis. World J Gastrointest Oncol 2022; 14(8): 1552-1561
URL: https://www.wjgnet.com/1948-5204/full/v14/i8/1552.htm
DOI: https://dx.doi.org/10.4251/wjgo.v14.i8.1552